CRESCENT BIOPHARMA, INC. Comprehensive Income
CRESCENT BIOPHARMA, INC. (CBIO) reported Comprehensive Income of -$24.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-07-30
- CRESCENT BIOPHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$24.84M.
- CRESCENT BIOPHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$23.28M.
- CRESCENT BIOPHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$92.40M.
- CRESCENT BIOPHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$24.61M.
- CRESCENT BIOPHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$153.94M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 0 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$24.84M 10-Q · filed 2026-07-30 | -$48.12M 10-Q · filed 2026-07-30 | -$140.52M derived: sum of 3 quarters · filed 2026-07-30 | -$165.12M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | -$23.28M 10-Q · filed 2026-04-29 | -$115.68M derived: sum of 2 quarters · filed 2026-04-29 | -$140.29M derived: sum of 3 quarters · filed 2026-04-29 | -$162.08M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | -$92.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$117.00M derived: sum of 2 quarters · filed 2026-02-26 | -$138.79M derived: sum of 3 quarters · filed 2026-07-30 | -$153.94M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$24.61M 10-Q · filed 2025-11-06 | -$46.40M derived: sum of 2 quarters · filed 2026-07-30 | -$61.55M 10-Q · filed 2025-11-06 | -$79.41M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | -$21.79M 10-Q · filed 2026-07-30 | -$36.94M 10-Q · filed 2026-07-30 | -$54.80M derived: sum of 3 quarters · filed 2026-07-30 | ||
| 2025-03-31 | -$15.15M 10-Q · filed 2026-04-29 | -$33.02M derived: sum of 2 quarters · filed 2026-04-29 | |||
| 2024-12-31 | -$17.87M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | -$2.63M 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |